
With an efficacy rate of 78% and WHO prequalification, the vaccine rollout aims to vaccinate 6.6 million children across 15 African countries by the end of 2024, marking an advancement in public health efforts to combat malaria's impact
Abene is currently a freelance writer and editor who contributes to Contagion. She is the former Assistant Editor for Contagion. She can be emailed at: sophiaabene@gmail.com.

With an efficacy rate of 78% and WHO prequalification, the vaccine rollout aims to vaccinate 6.6 million children across 15 African countries by the end of 2024, marking an advancement in public health efforts to combat malaria's impact

A recent report from the CDC highlights how the COVID-19 pandemic has heightened antimicrobial resistance, resulting in a 20% increase in hospital-onset infections caused by key resistant pathogens.

A Salmonella outbreak associated with Raw Farm in Fresno, California, has sickened at least 165 people, marking the largest US outbreak linked to raw milk in the past decade.

The OraQuick HCV self-test aims to improve testing access and help individuals detect the disease affecting an estimated 58 million people worldwide.

Epidemiologist Courtney Tillman, MPH, emphasizes the importance of routine vaccinations and awareness of occupational risks to prevent human infections.

Emily Hadley highlights study findings showing a higher incidence of Long COVID following initial infections compared to reinfections, particularly during the Omicron period among 3 million patients.

The FDA has overseen multiple product recalls this July thus far, including mystery infections linked to 58 illnesses, listeria, salmonella, plastic contamination, and more prompting the recall of various products.

Paul Radspinner, MBA, president and CEO of FluGen, addresses the safety profile, noting the low adverse event rates highlighting the safety and tolerability of the H3N2 M2SR influenza vaccine.

This week, the cucumber salmonella outbreak has tripled within a month, we debuted our Dr. Rodney E. Rohde podcast, launched the first episode of our complicated UTI Roundtable, and more this week from Contagion.

Adults 65 and older account for 70–85% of annual influenza-related deaths in the USA, underscoring the need for improved vaccine options, as current injectable vaccines show modest efficacy in many seasons.

Monitoring viral genetic changes in patients during ribavirin therapy could help identify those at risk for Hepatitis E Virus treatment failure.

As of July 2, 2024, the CDC reported 2,559 cases of dengue fever across the country with the majority of cases reported in Florida.

Matthew M Davis, MD, MAPP elaborates on how higher COVID-19 vaccination rates may curb the virus, alleviate childhood asthma symptoms, and protect against other common colds.

Christina Rafferty, BSc, an expert from the CDC, discusses the CLASS assay for swift and accurate detection of Anopheles stephensi, which is essential for controlling malaria spread and protecting communities from resurgence in Africa.

Despite extensive efforts, there remains no approved vaccine for norovirus, HilleVax decided to focus on a different development, a Phase 1 ready vaccine candidate for adults.

As of July 2nd, 2024, 449 people have been sickened and 124 people hospitalized.

Data gaps prompt the development of enhanced models revealing stagnant HCV rates, worsened by increasing injection drug use, requiring expanded testing and targeted interventions for underserved populations.

Despite initial concerns about vaccine safety, the study of nearly 3000 patients found no elevated risk of preterm birth associated with prenatal vaccination.

Mutations in YabG affect spore germination and substrate processing, offering insights into its essential functions in the lifecycle of C diff.

Colorado man infected with avian influenza, Novavax reveals promising results in JN1 covid vaccine efficacy, and recent roundups of c difficile news, and more from Contagion.

Boosted neutralization against variant XBB15 fades within 3 months post-first booster in transplant recipients but improves with a second, hybrid immunity enhances, suggesting 3-6 month boost intervals for solid organ transplant recipients.

Recent studies in Emerging Infectious Diseases have highlighted the persistence of highly pathogenic avian influenza A (H5N1) virus on milking equipment surfaces and its presence in dairy cattle mammary glands.

Enjoy a healthy and memorable 4th of July by prioritizing food safety while savoring delicious meals with family and friends.

Novavax, Inc has unveiled promising results regarding its JN1 COVID-19 vaccine's efficacy against emerging virus variants, including KP2 and KP3.

Identifying specific T cell states and immune markers opens promising avenues for personalized treatment approaches, understanding COVID-19 progression, and paving the way for targeted therapies to mitigate severe cases effectively.

Focused on microbial dynamics and inflammatory markers during remission, the study reveals persistent dysbiosis in the small intestine despite clinical improvements.

DDW 2024 highlighted advances in managing recurrent C difficile infections, emphasis on the effectiveness of live biotherapeutic products and the impact of antibiotic stewardship, and more ongoing efforts in combating C difficile.

The FDA recalls ice cream, orzo, and mixed nuts. Also this week, interviews with Jared Baeten, MD, PhD, on Lenacapavir's 100% efficacy against HIV, and Jason Roberts, PhD, on the promise of continuous β-Lactam against sepsis, and more from Contagion.

During today's CDC Advisory Committee on Immunization Practices (ACIP) meeting, committee members voted to recommend the FDA-authorized 2024-2025 COVID-19 vaccines for individuals aged 6 months and older. Additionally, they reaffirmed the existing influenza vaccination guidelines for the 2024-2025 season.

Jared Baeten, MD, PhD emphasizes the importance of the innovative PURPOSE 1 study in the fight against HIV, coinciding with National HIV Testing Day, today serves as a reminder of the ongoing efforts to expand testing access and develop new tools to combat HIV globally.